Literature DB >> 14705768

Investigation of c-myc and p53 gene alterations in the tumor and surgical borderline tissues of NSCLC and effects on clinicopathologic behavior: by the FISH technique.

T Yakut1, U Egeli, C Gebitekin.   

Abstract

Genetic alterations on the primary tumoral tissues and surgical borderline tissues of 51 patients with NSCLC on which radiotherapy and chemotherapy had not been performed were analyzed by using the FISH method with locus-specific probes for p53 tumor suppressor gene and c-myc oncogene and centromere-specific probes for chromosome 17 and chromosome 8 on which these genes are located. P53 deletions were detected in 7 patients (13.7%), c-myc amplification in 4 patients (7.8%), monosomy 17 in 2 patients (3.9%) and trisomy 8 in 3 patients (5.8%), and a high level of polyploidy in tumoral tissues of 6 patients (11.7%). P53 deletion and c-myc amplification were found at surgical borderlines of 2 patients and 1 patient, respectively. Although both p53 deletion and c-myc amplification have low frequency at surgical border tissues, not only their detection is important for the follow-up of recurrency and metastasis, but it is also important for genetical and pathological staging. The results of this study show that c-myc amplification in NSCLC is related to the shortening of survival (p < 0.01). C-myc amplification and p53 deletion are also effective for the occurrence of metastasis (p < 0.05) and the effect of c-myc amplification in this matter is much higher than p53 deletion. The gain or loss of copy number of chromosome 8 and monosomy 17 show parallel effects with c-myc amplification and p53 deletion, respectively, on the clinicopathological behavior of tumors.

Entities:  

Mesh:

Year:  2003        PMID: 14705768     DOI: 10.1007/s00408-003-1026-x

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  33 in total

1.  Cytologic examination of surgical margin of excised malignant pulmonary tumor: methods and early results.

Authors:  N Sawabata; T Mori; K Iuchi; H Maeda; M Ohta; O Kuwahara
Journal:  J Thorac Cardiovasc Surg       Date:  1999-03       Impact factor: 5.209

2.  p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients.

Authors:  V Skaug; D Ryberg; E H Kure; M O Arab; L Stangeland; A O Myking; A Haugen
Journal:  Clin Cancer Res       Date:  2000-03       Impact factor: 12.531

3.  Molecular and cytogenetic alterations in early stage of carcinogenesis of human lung.

Authors:  S Cheng; Y Gao; X Dong; Y Lu; Q An; T Tong; Y Wang
Journal:  Cancer Lett       Date:  2001-01       Impact factor: 8.679

4.  Analysis of chromosomal alterations in non-small cell lung cancer by multiplex-FISH, comparative genomic hybridization, and multicolor bar coding.

Authors:  M R Speicher; S Petersen; S Uhrig; I Jentsch; C Fauth; R Eils; I Petersen
Journal:  Lab Invest       Date:  2000-07       Impact factor: 5.662

5.  myc family oncogene amplification in tumor cell lines established from small cell lung cancer patients and its relationship to clinical status and course.

Authors:  B E Johnson; D C Ihde; R W Makuch; A F Gazdar; D N Carney; H Oie; E Russell; M M Nau; J D Minna
Journal:  J Clin Invest       Date:  1987-06       Impact factor: 14.808

6.  Frequent chromosome 8q gains in human small cell lung carcinoma detected by arbitrarily primed-PCR genomic fingerprinting.

Authors:  T Yamada; T Kohno; J M Navarro; S Ohwada; M Perucho; J Yokota
Journal:  Cancer Genet Cytogenet       Date:  2000-07-01

7.  myc family DNA amplification in small cell lung cancer patients' tumors and corresponding cell lines.

Authors:  B E Johnson; R W Makuch; A D Simmons; A F Gazdar; D Burch; A W Cashell
Journal:  Cancer Res       Date:  1988-09-15       Impact factor: 12.701

8.  Expression and amplification of myc gene family in small cell lung cancer and its relation to biological characteristics.

Authors:  T Takahashi; Y Obata; Y Sekido; T Hida; R Ueda; H Watanabe; Y Ariyoshi; T Sugiura; T Takahashi
Journal:  Cancer Res       Date:  1989-05-15       Impact factor: 12.701

9.  A novel combination of K-ras and myc amplification accompanied by point mutational activation of K-ras in a human lung cancer.

Authors:  Y Taya; K Hosogai; S Hirohashi; Y Shimosato; R Tsuchiya; N Tsuchida; M Fushimi; T Sekiya; S Nishimura
Journal:  EMBO J       Date:  1984-12-01       Impact factor: 11.598

10.  Loss of heterozygosity is related to p53 mutations and smoking in lung cancer.

Authors:  S Zienolddiny; D Ryberg; M O Arab; V Skaug; A Haugen
Journal:  Br J Cancer       Date:  2001-01       Impact factor: 7.640

View more
  5 in total

1.  The role of the c-Jun N-terminal kinase 2-α-isoform in non-small cell lung carcinoma tumorigenesis.

Authors:  R T Nitta; C A Del Vecchio; A H Chu; S S Mitra; A K Godwin; A J Wong
Journal:  Oncogene       Date:  2010-09-27       Impact factor: 9.867

2.  Expression of caspase-3 and c-myc in non-small cell lung cancer.

Authors:  Jin young Yoo; Chi Hong Kim; So Hyang Song; Byoung Yong Shim; Youn Ju Jeong; Meyung Im Ahn; Suji Kim; Deog Gon Cho; Min Seop Jo; Kyu Do Cho; Hong Joo Cho; Seok Jin Kang; Hoon Kyo Kim
Journal:  Cancer Res Treat       Date:  2004-10-31       Impact factor: 4.679

3.  Myc, Aurora Kinase A, and mutant p53(R172H) co-operate in a mouse model of metastatic skin carcinoma.

Authors:  E C Torchia; C Caulin; S Acin; T Terzian; B J Kubick; N F Box; D R Roop
Journal:  Oncogene       Date:  2011-10-03       Impact factor: 9.867

4.  Comparative genomic hybridization array analysis and real-time PCR reveals genomic copy number alteration for lung adenocarcinomas.

Authors:  Jin Soo Choi; Long Tai Zheng; Eunyoung Ha; Yun Jeong Lim; Yeul Hong Kim; Young-Pil Wang; Young Lim
Journal:  Lung       Date:  2006-11-03       Impact factor: 2.584

5.  MYC amplification is associated with poor survival in small cell lung cancer: a chromogenic in situ hybridization study.

Authors:  Rita de Cássia S Alves; Rosalva Thereza Meurer; Adriana Vial Roehe
Journal:  J Cancer Res Clin Oncol       Date:  2014-07-11       Impact factor: 4.553

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.